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ABSTRACT
Background. Repeat sentinel lymph node biopsy (rSLNB)
has increasingly been used in patients with ipsilateral
breast tumor recurrence (IBTR). The safety in terms of
regional disease control after this procedure remains
unclear. This study evaluates occurrence of regional
recurrence as first event in patients with IBTR and negative
rSLNB, treated without additional lymph node dissection.
Patients and Methods. Data were obtained from the
Sentinel Node and Recurrent Breast Cancer (SNARB)
study. In 201 patients, tumor-negative rSLNB was obtained
without performing additional lymph node dissections.
Results. With median follow-up of 4.7 (range 0.9–12.7)
years, regional recurrence occurred after median time of
3.0 (range 0.4–6.7) years in 4.5% (N = 9) of patients as
first event after IBTR and rSLNB. In four of these nine
patients, the site of recurrence was in concordance with the
anatomical location of rSLNB. Two of the nine recurrences
were reported in the ipsilateral axilla, resulting in an ipsi-
lateral axillary regional recurrence rate of 1.0%. In the
other seven patients, regional recurrence occurred in
aberrant basins. Univariable analysis showed that triple-
negative IBTR and lower amount of radioactive-labeled
tracer (99mtechnetium) used during rSLNB were associated
with developing regional recurrence as first event after
negative rSLNB (P\ 0.05).
Conclusions. The risk of developing regional recurrence
after negative rSLNB is low. The low relapse rate supports
the safety of rSLNB as primary nodal staging tool in IBTR.
The time has come for clinical guidelines to adopt rSLNB
as axillary staging tool in patients with IBTR.
During recent decades, sentinel lymph node biopsy
(SLNB) has emerged and is currently accepted as the new
standard practice for axillary staging in patients with pri-
mary breast cancer.1 Following the growing confidence in
the efficacy of SLNB, questions were raised regarding use
of this procedure in patients with ipsilateral breast tumor
recurrence (IBTR). To date, there is no standard practice
regarding axillary staging in IBTR,2 hence several studies
have evaluated repeat SLNB (rSLNB) in the recurrent
setting. These studies showed feasibility of repeat sentinel
node in approximately 65% of cases and revealed a role for
this procedure in tailoring adjuvant treatment plans.3,4
However, safety in terms of regional disease control and
regional lymph node recurrence after rSLNB in patients
with IBTR remains unclear.
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In primary breast cancer, regional disease control after
SLNB without completion axillary lymph node dissection
(cALND) has been investigated critically. False-negative
rates of approximately 5%, very low regional recurrence
rates, and survival rates comparable to those following
ALND justified the conclusion that ALND could be safely
omitted in sentinel lymph node-negative patients,1,5–7
thereby sparing patients with primary breast cancer from
the morbidity associated with ALND.8,9
For patients with IBTR and tumor-negative rSLNB,
clinically relevant treatment changes were also observed.
With negative predictive value of 94%, omission of addi-
tional lymph node dissection was assumed to be safe.3
Nonetheless, long-term follow-up data on regional recur-
rence after negative rSLNB have not yet been published.
For rSLNB to become an equivalent standard of care in the
IBTR setting as well, it is imperative to ensure high
regional disease control. Therefore, the aim of this study is
to evaluate occurrence of regional recurrence as first event
after negative rSNLB in patients with nonmetastatic IBTR,
treated with curative intent and without cALND.
PATIENTS AND METHODS
SNARB Study Design
The SNARB study is a multicenter national registration
study in which 36 Dutch hospitals participated. In the
period from February 2008 to July 2011, data of 150
patients with recurrent breast cancer were prospectively
entered into the database.10 Subsequently, from August
2011 to December 2014, data from 386 additional patients
were retrospectively entered into the database. The addi-
tional data were derived from 29 of the 36 initial
participating hospitals. Patients with clinically apparent
ipsilateral or contralateral lymph node metastases and
patients with distant metastases were excluded.3 A total of
536 patients, over 18 years old with operable locally
recurrent breast cancer and staged with rSLNB, were
included. During rSLNB, the dual-mapping technique with
both 99mtechneticum and blue dye was used. From January
2017 to July 2017, follow-up data of the 536 included
SNARB patients were collected and entered into the
database.
Patients
Patients with IBTR and successful rSLNB were con-
sidered eligible for inclusion. Patients who underwent
additional axillary lymph node dissection as validation
procedure after detection of a negative sentinel lymph node
were excluded. Patients with either micro- or
macrometastases in their sentinel lymph node were exclu-
ded. Sentinel lymph nodes containing isolated tumor cells
(ITC) (small clusters of cells\ 0.2 mm and/or fewer than
200 cells) were classified as node negative.
Regional Recurrence
The primary endpoint of this study was regional lymph
node recurrence as first event after curative treatment of
IBTR. Regional recurrence was defined as any evidence of
disease found in ipsilateral intramammary nodes, ipsi- and
contralateral internal mammary nodes, ipsi- and contralat-
eral axillary nodes, and ipsi- and contralateral infra- and
supraclavicular nodes. Lymph node recurrences found
outside these nodal basins were defined as distant meta-
static disease. In the recently published Maastricht Delphi
Consensus statement on the definition of regional events,
only ipsilateral nodal recurrences (either axillary or in other
ipsilateral nodal basins) were considered as regional
recurrences.11 Based on earlier rSLNB studies,3,12 we state
that the definition of a regional recurrence after IBTR
should be broadened and should also include contralateral
nodes, since lymphatic drainage towards these basins is
common.4,13,14 Therefore, we considered contralateral
events as regional recurrences.
Regional recurrences were registered if they occurred as
first event after negative rSLNB or when diagnosed con-
currently with local recurrences in the previous treated
breast. Patients with regional recurrence coincident with or
after diagnosis of distant disease were not reported as
having regional recurrence as first event. In patients with
second IBTR or newly diagnosed contralateral breast
tumor as first event without clinically (i.e., physical
examination or after imaging studies) relevant regional
lymph node metastases, possible lymph node metastases
found during a second rSLNB were not regarded as
regional recurrence.
Follow-Up
General practitioners were actively contacted for addi-
tional follow-up information when hospital records showed
no outpatient clinic visits for more than 1 year. Date of last
follow-up was documented as last visit to the outpatient
clinic, date of visit to the general practitioner, or date of
death in case the patient had deceased.
Follow-up time was defined as time from date of surgery
for initial IBTR to date of last follow-up. Time to regional
recurrence was defined as time between treatment of IBTR
and date of diagnosis of regional recurrence as first event
after IBTR.
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Statistics
The variables used (see Supporting Information) were
compared between patients with regional recurrence as first
event and patients with no regional recurrence. Statistical
significance was tested using Pearson Chi square test and
Fisher exact test for categorical variables. For continuous
variables, Mann–Whitney U test or independent sample
t test was used when appropriate. Two-sided P-
value\ 0.05 was considered statistically significant. Sur-
vival analysis, using the Kaplan–Meier method, was
performed to calculate the 5-year risk of regional recur-
rence after IBTR. Data analysis was performed using SPSS
version 24 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patients
Follow-up data were collected for 536 patients. As 21
patients were lost to follow-up due to file loss, emigration,
or loss of informed consent, 515 patients remained avail-
able for analysis. Of these 515 patients, 230 patients had
successful negative rSLNB, of whom 29 patients were
excluded since they underwent additional lymph node
dissection. The median age of the remaining 201 patients at
time of IBTR was 63.5 (range 34–87) years. The median
time from primary surgery to diagnosis of IBTR was 8.5
(range 0.4–30) years. After treatment of IBTR, 22.4% of
patients underwent (re)irradiation to the chest wall or
regional lymph node basins (N = 45). Of all patients,
63.2% received adjuvant systemic treatment (N = 127).
Adjuvant endocrine therapy was administered in 56.7%
(N = 114) and adjuvant chemotherapy in 16.9% of the
patients (N = 34). Patient characteristics are summarized
in Table 1.
Regional Recurrence
With median follow-up of 4.7 (range 0.9–12.7) years
from IBTR, nine patients were diagnosed with regional
recurrence as first event after negative rSLNB (4.5%).
These nine regional recurrences occurred after median time
of 3.0 (range 0.4–6.7) years. Therefore, the overall regional
recurrence rate as first event was 4.5%, with 5-year
regional recurrence-free rate of 95.4% [95% confidence
interval (CI) 91.9–98.9%]. Of the nine patients with
regional recurrence, two patients experienced regional
recurrence in the ipsilateral axilla, resulting in an ipsilateral
axillary recurrence rate of 1% (Table 2).
Within the nine patients with regional recurrence, six
recurrences were symptomatic (i.e., patients visited the
outpatient clinic with lymph node swelling or other
localized complaints in an interval between planned fol-
low-up points). The other three recurrences were detected
during routine follow-up: two patients during scheduled
echography and one patient during scheduled positron
emission tomography scan (Table 2).
Location of Regional Recurrence
Two patients experienced ipsilateral axillary recurrence.
One of these patients underwent breast surgery alone
(without SLNB or ALND) at the time of the primary breast
tumor. During treatment for IBTR, the negative rSLNB
was located in the ipsilateral axilla and completion ALND
was omitted. Thus, this patient had a relatively intact
ipsilateral axilla and developed an ipsilateral axillary
recurrence 59 months after treatment for IBTR. The other
patient received ALND during primary treatment. At the
time of IBTR, the negative rSLNB was located in the
contralateral axilla. Forty-three months after IBTR, an
ipsilateral axillary recurrence, localized near the sub-
scapular muscle, was diagnosed.
The remaining seven patients developed nodal recur-
rence outside of the ipsilateral axilla: three in the ipsilateral
supraclavicular basin, one in the ipsilateral internal mam-
mary chain, and three in the contralateral axilla. In four of
the nine patients (44.4%), the site of regional recurrence
was in concordance with the site of the rSLNB on lym-
phoscintigraphy and during rSLNB surgery (one ipsilateral
axilla, one ipsilateral internal mammary chain, and two
contralateral axilla).
Adjuvant Radiotherapy to the Regional Lymph Node
Basins
Of all patients, 88.1% (N = 177) were primarily treated
with adjuvant radiotherapy (for detailed information on
location of radiotherapy, see Supporting Information).
After treatment of IBTR, 22.4% (N = 45) of patients
underwent (re)irradiation, of whom 35 patients received
radiotherapy to the chest wall, seven patients to the breast,
and one to the chest wall and infraclavicular region because
of an aberrant node on lymphoscintigram, while in two
patients the region was unknown. Two of the nine patients
diagnosed with regional recurrence after IBTR received
radiotherapy to the chest wall (Table 2).
Comparison of Variables Between Patients With
and Without Regional Recurrence as First Event After
IBTR
Comparing patients who developed regional recurrence
with those who did not, we did not find significant differ-
ences between the groups regarding disease-free interval
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TABLE 1 Clinicopathological characteristics of all patients with IBTR and negative repeat sentinel lymph node biopsy, without additional
lymph node dissection (N = 201)
Total group
(N = 201)
Regional recurrence
(N = 9)
No regional recurrence
(N = 192)
P-
value
Age primary tumor, median years (range) 51.0 (26–80) 49.0 (40–69) 51.0 (26–80) 0.758
Age primary tumor, years 0.719
\ 35 8 (4.0%) – 8 (4.2%)
35–59 137 (68.5%) 6 (66.7%) 131 (68.6%)
60–69 45 (22.5%) 3 (33.3%) 42 (22.0%)
C 70 10 (5.0%) – 10 (5.2%)
Primary surgery 0.679
Mastectomy 38 (18.9%) 2 (22.2%) 36 (18.8%)
Breast-conserving surgery 163 (81.1%) 7 (77.8%) 156 (81.3%)
Primary SN 0.411
Negative 88 (43.8%) 2 (22.2%) 86 (44.8%)
Positive 16 (8.0%) 1 (11.1%) 15 (7.8%)
No SN 97 (48.3%) 6 (66.7%) 91 (47.4%)
Primary axillary surgery 0.512
No axillary staging 18 (9.0%) 2 (22.2%) 16 (8.3%)
SN negative 86 (42.8%) 2 (22.2%) 84 (43.8%)
SN positive, cALND 13 (6.4%) 1 (11.1%) 12 (6.3%)
SN positive, no cALND 3 (1.5%) – 3 (1.6%)
ALND 81 (40.1%) 4 (44.4%) 77 (40.1%)
Primary nodal status 0.645
Negative 145 (72.1%) 6 (66.7%) 139 (72.4%)
Positive 31 (15.4%) 1 (11.1%) 30 (15.6%)
Unknown 25 (12.4%) 2 (22.2%) 23 (12.0%)
Primary tumor size 0.110
\ 20 mm 116 (57.7%) 5 (55.6%) 111 (57.8%)
21–50 mm 33 (16.4%) 1 (11.1%) 32 (16.7%)
[ 50 mm 3 (1.5%) 1 (11.1%) 2 (1.0%)
Unknown 49 (24.4%) 2 (22.2%) 47 (24.5%)
Primary tumor grade 0.071
I 38 (18.9%) – 38 (19.8%)
II 47 (23.4%) – 47 (24.5%)
III 30 (14.9%) 2 (22.2%) 28 (14.6%)
Unknown 86 (42.8%) 7 (77.8%) 79 (41.1%)
Receptor status of primary tumor 0.017
Triple negative 8 (4.0%) 1 (11.1%) 7 (3.6%)
HR- Her2? 2 (1.0%) 1 (11.1% 1 (0.5%)
HR? Her2? 3 (1.5%) – 3 (1.6%)
HR? Her2- 58 (28.9%) 1 (11.1%) 57 (29.7%)
Unknown 130 (64.7%) 6 (66.7%) 124 (64.6%)
Hormone status primary tumor 0.270
ER and PR negative 18 (9.0%) 2 (22.2%) 16 (8.3%)
ER/PR positive 106 (52.7%) 3 (33.3%) 103 (53.6%)
Unknown 77 (38.3%) 4 (44.4%) 73 (38.0%)
Time from primary surgery to IBTR diagnosis
Median, months (range) 106.5 (4–361) 143.0 (15–213) 105.0 (4–361) 0.902
Median, years (range) 8.5 (0–30) 11.0 (1–17) 8.0 (0–30) 0.940
\ 2 years 19 (9.5%) 2 (22.2%) 17 (8.9%) 0.414
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TABLE 1 continued
Total group
(N = 201)
Regional recurrence
(N = 9)
No regional recurrence
(N = 192)
P-
value
2.1–5 years 39 (19.4%) 1 (11.1%) 38 (19.8%)
5.1–10 years 50 (24.9%) 1 (11.1%) 49 (25.5%)
[ 10 years 92 (45.8%) 5 (55.6%) 87 (45.3%)
Age IBTR, median years (range) 63.5 (34–87) 65.0 (41–76) 63.0 (34–87) 0.658
Age IBTR, years 0.951
\ 35 1 (0.5%) – 1 (0.5%)
35–59 72 (35.8%) 4 (44.4%) 68 (35.4%)
60–69 74 (36.8%) 3 (33.3%) 71 (37.0%)
C 70 54 (26.9%) 2 (22.2%) 52 (27.1%)
Location IBTR 0.679
Breast 163 (81.1%) 7 (77.8%) 156 (81.3%)
Mastectomy scar or chest wall 38 (18.9%) 2 (22.2%) 36 (18.8%)
Repeat SN aberrant 0.873
Yes 97 (48.3%) 5 (55.6%) 92 (47.9%)
No 102 (50.7%) 4 (44.4%) 98 (51.0%)
Unknown 2 (1.0%) – 2 (1.0%)
Repeat SN tracer amount, MBq median
(range)
109 (20.0–385.0) 80.0 (30.0–117.0) 110.0 (20.0–385.0) 0.044
Tumor size IBTR 0.663
\ 20 mm 145 (72.1%) 8 (88.9%) 137 (71.4%)
21–50 mm 34 (16.9%) 1 (11.1%) 33 (17.2%)
[ 50 mm 2 (1.0%) – 2 (1.0%)
Unknown 20 (10.0%) – 20 (10.4%)
Tumor grade IBTR 0.035
I 40 (19.9%) – 40 (20.8%)
II 85 (42.3%) 2 (22.2%) 83 (43.2%)
III 64 (31.8%) 5 (55.6%) 59 (30.7%)
Unknown 12 (6.0%) 2 (22.2%) 10 (5.2%)
Receptor status IBTR 0.002
Triple negative 25 (12.4%) 5 (55.6%) 20 (10.4%)
HR- Her2? 6 (3.0%) – 6 (3.1%)
HR? Her2? 11 (5.5%) – 11 (5.7%)
HR? Her2- 129 (64.2%) 4 (44.4%) 125 (65.1%)
Unknown 30 (14.9%) – 30 (15.6%)
Radiotherapy IBTR 1.000
Yes 45 (22.4%) 2 (22.2%) 43 (22.4%)
No 156 (77.6%) 7 (77.8%) 149 (77.6%)
Systemic therapy IBTR 0.728
Yes 127 (63.2%) 5 (55.6%) 122 (63.5%)
No 74 (36.8%) 4 (44.4%) 70 (36.5%)
Endocrine therapy IBTR
Yes 114 (56.7%) 5 (55.6%) 110 (57.3%) 0.505
No 87 (43.3%) 4 (44.4%) 82 (42.7%)
Chemotherapy IBTR 1.000
Yes 34 (16.9%) 1 (11.1%) 33 (17.2%)
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(DFI), age or tumor size during primary and recurrent
breast cancer (Table 1). Likewise, there were no significant
differences in administration of adjuvant therapy following
IBTR between the two patient cohorts.
Of the nine patients with regional recurrence as first
event after negative rSLNB, 55.4% had a triple-negative
recurrent tumor compared with 10.4% of the patients
without regional recurrence as first event (P = 0.002).
Furthermore, grade III IBTR was found in 55.6% of
patients with regional recurrence compared with 30.7% of
patients without regional recurrence (P = 0.035). Lastly,
patients with regional recurrence as first event were
injected with a significantly lower amount of radioactively
labeled tracer (99mtechnetium) during rSLNB (median
80.0 MBq) compared with patients without regional
recurrence as first event (median 110.0 MBq) (P = 0.044)
(Table 1).
DISCUSSION
Data from this study showed that the risk of developing
regional recurrence after negative rSLNB in patients with
IBTR is low. The low relapse rate supports the safety of
rSLNB as nodal staging procedure in the IBTR setting.
TABLE 1 continued
Total group
(N = 201)
Regional recurrence
(N = 9)
No regional recurrence
(N = 192)
P-
value
No 167 (83.1%) 8 (88.9%) 159 (82.8%)
Univariable analyses compared patients with regional recurrence (N = 9) and patients without regional recurrence (N = 192)
IBTR ipsilateral breast tumor recurrence, ALND axillary lymph node dissection, cALND completion axillary lymph node dissection, SN sentinel
node, mm millimeter, HR hormone receptor, ER estrogen, PR progesterone, MBq megabecquerel, Her2 human epidermal growth receptor 2
TABLE 2 Regional recurrence after negative repeat sentinel lymph node biopsy, without additional lymph node dissection
Regional
recurrence
Follow-up
IBTR
(months)
rSN location LM rSN location
surgical
harvested
DFI 1st to 2nd
tumor
(months)
Primary
axillary
staging
Primary
adjuvant (RT,
CT, HT)
Secondary
adjuvant (CT,
RT, HT)
Ipsilateral axilla 59 Ipsilateral axilla Ipsilateral axilla 61 None RT breast HT
Ipsilateral axilla 43 Contralateral axilla Contralateral
axilla
19 SN?,
cALND
RT breast, RT
axilla n.a.,
CT
None
Ipsilateral
Supraclavicular
40 Ipsilateral internal
mammary chain/
intramammary
Ipsilateral axilla 143 ALND None RT chest, HT
Ipsilateral
supraclavicular
65 Ipsilateral internal
mammary chain/
intramammary
Ipsilateral
internal
mammary
chain
187 ALND RT breast HT
Ipsilateral
supraclavicular
9 Ipsilateral axilla Ipsilateral axilla 15 SN- None RT chest
Ipsilateral
internal
mammary
chain
4 Ipsilateral internal
mammary chain/
intramammary
Ipsilateral
internal
mammary
chain
196 None RT breast None
Contralateral
axilla
80 Contralateral axilla Contralateral
axilla
213 ALND RT breast, RT
axilla n.a.
CT
Contralateral
axilla
15 Ipsilateral axilla Ipsilateral axilla 30 SN– RT breast, HT HT
Contralateral
axilla
9 Contralateral axilla Contralateral
axilla
180 ALND RT breast None
DFI disease-free interval, IBTR ipsilateral breast tumor recurrence, rSN repeat sentinel node, LM lymphoscintigram, RT radiotherapy, CT
chemotherapy, HT hormone therapy, SN? sentinel node positive, cALND completion axillary lymph node dissection, ALND axillary lymph node
dissection, SN- sentinel node negative, n.a. not available
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After median follow-up of 4.7 (range 0.9–12.7) years,
regional recurrence occurred in 4.5% of patients after
negative rSLNB. To date, other studies reporting on
regional recurrence after negative rSLNB, other than ipsi-
lateral axillary recurrences only, are limited2,12,15–27
(Table 3). As shown in Table 3, the number of patients in
all these studies were relatively small; moreover, defini-
tions of regional recurrence could not be deduced from the
articles. Therefore, comparison of these results with our
regional recurrence rate of 4.5% could not be made.
In the primary setting, the highest incidence of axillary
recurrence occurred between 24 and 42 months.28
Recently, Geurts et al. published data about first and sec-
ond recurrences after curative treatment of primary breast
cancer, reporting that the maximum risk of regional
recurrence after IBTR was reached within the first year
following treatment.29 In this study with median follow-up
of 4.7 years, sufficient time has elapsed to assume that,
after a relatively long follow-up period, the risk of devel-
oping regional recurrence after negative rSLNB is low.
In the recent past, performance of ipsilateral ALND in
the setting of IBTR was considered as standard care for
optimal regional disease control. Therefore, the very low
rate of ipsilateral axillary recurrence (1.0%) after negative
rSLNB in this study is most interesting. As shown in
Table 3,2,12,15–27 other studies reporting on ipsilateral
axillary recurrence after negative rSLNB showed results
that vary between 0 and 9%. Intra et al. published a study
on rSLNB with a relatively large number of patients. In
that study, an ipsilateral axillary recurrence rate of 3.9%
was described, during median follow-up of 5 years.12
However, that rate was observed in a cohort of patients
with negative repeat sentinel lymph nodes and positive
repeat sentinel lymph nodes followed by performance of
cALND.
During introduction of the SLNB procedure in the pri-
mary setting, an ipsilateral axillary recurrence rate of 5%
was accepted to replace cALND by SLNB as standard
axillary staging tool.30 Later on, Wely et al. reported an
even lower ipsilateral axillary recurrence rate of 1.6% after
median follow-up of 77 months.28 Analogous to these
percentages, it seems acceptable that the 1.0% ipsilateral
axillary recurrence rate reported herein justifies replace-
ment of ipsilateral ALND by rSLNB in case of clinically
node-negative IBTR.
After radiotherapy and surgery of the breast and/or
axilla, drainage in rSLNB outside the ipsilateral axilla is
described in 18–70% of patients.3,23,31 In this cohort of
patients, 48.3% of the rSLNBs were located in an aberrant
lymph node station. With the visualization of aberrant
lymph drainage in IBTR patients, it is assumed that rSLNB
is a more accurate staging method than ipsilateral ALND.3
TABLE 3 Articles describing regional recurrence in patients with IBTR and negative repeat sentinel lymph node biopsy, without additional
lymph node dissection
Author Patients (N) Follow-up after IBTR (months) Regional recurrence Ipsilateral axillary recurrence
Agarwal et al.15 1 25 0 (0%) 0 (0%)
Boughey et al.17 8 Median 13 (of 13 patients) – 0 (0%)
Roumen et al.24 2 Mean 14 0 (0%) 0 (0%)
Barone et al.16 14 Mean 15 (of 19 patients) – 0(0%)
Port et al.23 31 Mean 26.4 (of 115 patients) – 0 (0%)
Cox et al.18 36 Mean 26 (of 56 patients) – 0(0%)
Karam et al.20 7 Mean 33.3 (of 11 patients) – 1/7 (14.3%)
Kaur et al.22 3 Mean 21.6 (of 45 patients) – 0 (0%)
Derkx et al.2 2 Mean 12 0 (0%) 0 (0%)
Tokmak et al.25 5 Mean 27 (of 6 patients) 0 (0%) 0 (0%)
Matsumoto et al.27 26 Median 40.3 (of 28 patients) – 0 (0%)
Intra et al.12 171 All 60 (of 196 patients) – 8/212 (3.9%)a
Uth et al.26 47 Median 38 (of 144 patients) – 0 (0%)
Karanlik et al.21 15 Mean 36 (of 39 patients) 0 (0%) 0 (0%)
Johnson et al.19 8 Median 55.5 (of 12 patients) 1/8 (12.5%)b 0 (0%)
15 Articles 376 patients Range 12–60 (1–3 years) 1/33 (3.0%) 9/376 (2.4%)
DFI disease-free interval, IBTR ipsilateral breast tumor recurrence
aIntra et al. including 25 positive rSLNB with cALND
bJohnson et al.: internal mammary node recurrence
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Hence, for at least 48% of our patients, ipsilateral ALND
would not have been an accurate staging tool and the
aberrant rSNs would have remained unnoticed in absence
of rSLNB. With 56% of patients with regional recurrence
having an aberrant rSN, it could be hypothesized that one
should (re)irradiate aberrant basins on a preventive basis,
despite the node-negative outcome. However, this seems to
be overtreatment, since the aberrant regional recurrence
rate is very low.
Only the 1% of patients with ipsilateral axillary recur-
rence after rSLNB could have had a possible benefit from
ALND. The other seven (3.5%) regional recurrences were
found outside the ipsilateral axilla. These aberrant sites of
recurrence were in concordance with the site of the har-
vested rSLNB in three cases. For these patients, the
histologic outcome of rSLNB was possibly false negative.
In four other patients, the regional recurrence was not
concordant with the location of the rSLNB. One explana-
tion could be that rSLNB in IBTR is a technically
challenging procedure. As published before, injection with
a larger amount of tracer leads to a higher identification
rate.32 In this study, patients with regional recurrence had a
significantly lower amount of tracer injected. Injection of a
higher tracer dose might have led to identification of repeat
sentinel lymph nodes in additional basins. It could also be
hypothesized that lymph drainage of the IBTR might have
been multidirectional, and the rSLNB identified only one
basin.
In this study, 55.4% of patients with regional re-recur-
rence had triple-negative IBTR. Therefore, triple-negative
disease seems to be a risk factor for developing regional re-
recurrence. Although the numbers are small, these findings
are comparable to identified risk factors for regional
recurrence after primary SLNB.33,34 Patients with estrogen
receptor (ER)-negative tumors (in particular, triple-nega-
tive tumors) have increased risk of developing regional
recurrence after primary SLNB.33,34 Clinicians could opt
for more aggressive treatment in patients with triple-neg-
ative IBTR. In this study, only 17% of patients with IBTR
were treated with adjuvant chemotherapy, while the
CALOR trial provided evidence of a beneficial effect of
adjuvant systemic treatment on overall and disease-free
survival for IBTR, especially ER-negative IBTR.35
Some caveats have to be considered regarding this
study. Given the small number of regional events, multi-
variable analyses were inappropriate and limited statistical
conclusions could be made. Furthermore, a randomized
controlled trial comparing rSLNB with ALND would have
been preferable. On the other hand, such a trial would most
probably be underpowered due to the low incidence of
recurrent breast cancer and regional recurrence after
recurrent breast cancer. Despite these limitations, the pre-
sent study is unique in the fact that follow-up data were
available for a large cohort of patients with IBTR and
negative rSLNB. No other studies on regional recurrence
after negative rSLNB have included such a large patient
population. Furthermore, this is a multicenter study,
including data from different types of hospital in The
Netherlands with different breast cancer volumes. Going
forward, further research is encouraged in the field of
rSLNB to optimize the prognostic value of this procedure,
but on the basis of present evidence, cALND can be safely
omitted after negative rSLNB.
CONCLUSIONS
The 5-year risk of developing regional recurrence after
negative rSLNB without subsequent ALND in patients
with IBTR is less than 5%, with only 1% being located in
the ipsilateral axilla. This low relapse rate provides further
evidence that rSLNB is a safe primary staging method in
IBTR, in terms of regional recurrence. Based on these data,
we suggest to adopt rSLNB as standard of care in IBTR
and to omit ipsilateral ALND.
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